COMMUNIQUÉS West-GlobeNewswire

Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans

12/11/2018 - 13:07

Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company [...]

Myriad to Present New Data from Its Industry-Leading Portfolio of Genetic Tests for Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

12/11/2018 - 13:05

SALT LAKE CITY, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 studies will be featured at the San Antonio Breast Cancer [...]

Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

12/11/2018 - 13:05

First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology [...]

Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences

12/11/2018 - 13:01

Press release - No. 23 / 2018 Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences Copenhagen, November 12, 2018 - Britt Meelby Jensen, President and Chief Executive Officer of Zealand [...]

Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published

12/11/2018 - 13:01

Press release November 12, 2018 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEELAND OR ANY OTHER [...]

Ziopharm Oncology to Host Conference Call Today at 8 a.m.

12/11/2018 - 13:01

BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today will host a webcast and conference call today, Nov. 12, at 8 a.m. ET. On the call, management will discuss recent corporate [...]

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)

12/11/2018 - 13:00

WATERTOWN, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]

Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week

12/11/2018 - 13:00

Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Preclinical Data on New Mechanism Antibiotic SMT- [...]

Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial

12/11/2018 - 13:00

Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) announced today that [...]

Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer

12/11/2018 - 13:00

BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. , (Nasdaq:ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in [...]

Bioxytran Inc’s New Compound for Treating Strokes Will be the Company’s New Health Mission Moving Forward

12/11/2018 - 13:00

Company Formerly Known as U.S. Rare Earth Minerals, Inc. Focusing on First-In-Class Ischemic Stroke Treatment BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- U.S. Rare Earth Minerals, Inc. today announced that it has changed [...]

Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria

12/11/2018 - 13:00

PDUFA date set for June 30, 2019 SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug [...]

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018

12/11/2018 - 13:00

Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-Year Gross Profit for First Nine Months of 2018 was $20.2 million, a 1% Decrease Year-Over-Year Adjusted EBITDA was $7.4 Million [...]

Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

12/11/2018 - 13:00

CRANBURY, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse [...]

Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update

12/11/2018 - 13:00

– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 drug class – – Company [...]

Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018

12/11/2018 - 13:00

Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical [...]

ContraFect Appoints Michael Messinger as Chief Financial Officer

12/11/2018 - 13:00

YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]

Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

12/11/2018 - 13:00

- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference call today at 8:30 a.m. ET [...]

Ziopharm Oncology Announces $50 Million Private Placement

12/11/2018 - 12:58

BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to [...]